Cardiac side effects of targeted therapies.
To review common cardiac side effects, their clinical presentation, and recommendations for assessment and management of patients receiving molecularly targeted cancer therapies. Peer-reviewed literature. Although there is no established guideline for pretreatment cardiac evaluation and monitoring of patients receiving molecularly targeted agents, data currently supports the need for early risk identification and prevention/reduction strategies. As nurses, we have a unique opportunity to help improve and maintain the quality of life of cancer survivors. Cardiovascular assessment and prevention/reduction strategies are essential to reduce risk of cardiovascular disease, promote optimal quality of life, and improve survival outcomes in patients receiving molecularly targeted cancer treatment.